Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide vs Dulaglutide as add-on to Metformin in Type 2 Diabetes
NCT02648204Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2016
- Primary completion
- Apr 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Jan 2016; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02648204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02648204.